GLP-1/GIP/glucagon receptor (triple) drugs for Type 2 Diabetes

3 tracked GLP-1/GIP/glucagon receptor (triple) drugs in the Type 2 Diabetes race. The class explanation lives on the GLP-1/GIP/glucagon receptor (triple) page; the full indication pipeline across every mechanism is on the Type 2 Diabetes page.

2 Phase 31 Phase 2

Head-to-head evidence: HM15275 vs retatrutide · retatrutide vs UBT251

The roster

← all GLP-1/GIP/glucagon receptor (triple) drugs